When it comes to owning penny stocks, investors need to focus on only the ones with the biggest potential. These are the stocks trading for pennies that can soon be trading at $.05, then $.10, then $.25, and before you know it over $1. This is why we invest in penny stocks. We at Insider Financial are looking for big returns and to capture those big returns, you have to find the must-own stocks like BRTXQ stock.
We wrote up BRTXQ stock last month when it was $.013 a share. We identified BRTXQ stock as one of those must-own stocks, which you can read here. We said at the time that BRTXQ stock represented a winning lotto ticket and investors just needed to be patient. We also said:
Right now, all that is required is for Judge Grossman to say one word – EFFECTIVE. We don’t know when that will happen. A lot depends on his schedule with holidays, COVID-19, and a logjam of cases on the docket. Interested shareholders can monitor the developments on PACER. We at Insider Financial will also be following along and updating our subscribers.
Just as we said, we got the EFFECTIVE news on October 30th. While we updated our subscribers when the EFFECTIVE news hit, we are now updating our regular readers on what’s next.
First up, here’s little background info for those not familiar with BRTXQ stock. BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The company’s two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders.
What’s most notable about BRTXQ stock is that it’s a former NASDAQ runner that traded at $40 a share in 2012. The reason the company ended up on the OTC Markets and with the Q symbol is that prior management failed to raise between $10 million and $12 million for a clinical trial of its stem-cell therapy for bulging spinal discs. The trial was authorized by the U.S. Food and Drug Administration in 2017 when BRTXQ stock was $5 a share.
You see, there’s tremendous value in the IP of BRTXQ stock. This is why board member and intellectual property attorney John M. Desmarais loaned the company $1.3 million, including interest, in 2016-17. Desmarais bid $500,000 through another business he owns, Phoenix Cell Group Holdings LLC to take control of BRTXQ stock in bankruptcy court. Phoenix was also providing $1.4 million to keep BioRestorative operating, the filings stated.
Desmarais game plan was to get the intellectual property owned by BRTXQ on the cheap. Basically, he thought he could steal the company. After all, he is a patent attorney and was a board member. He knows the true value of the patents!
Seeing what was happening, Actus Fund stepped in and partnered with the company to fund the company through bankruptcy and complete the FDA trials. In the U.S. and Europe, over 100 million people suffer from chronic back pain. Spinal fusion surgery costs $110,000. Discectomy costs anywhere from $20,000 to $50,000 and disk replacement surgery is $80,000 to $150,000. Compare this to what BRTXQ costs!
This is a multi-billion-dollar opportunity for BRTXQ. All that is required is $10 million to $12 million for the trial and $2 million to $3 million in debtor financing. This is what Actus Fund realizes and why they have stepped in.
What’s Next For BRTXQ Stock?
The EFFECTIVE date is 14 business days after the CONFIRMATION date of October 30th, so that will be November 19th. The 8-K needs to be filed 4 days after CONFIRMATION, so we will see the 8-K on November 4th.
The reorganization plan that was CONFIRMED by Judge Robert E. Grossman calls for the company to emerge from bankruptcy with common shares intact, ready to begin phase 2 trials and get BRTXQ stock back on NASDAQ or the NYSE. This is what the plan called for. This is not a mystery of oh what will happen in bankruptcy court. It was all spelled out on PACER. This is why we at Insider Financial and a few other smart penny stock investors have been pounding the table on BRTXQ as a must-own. There were no games being played with BRTXQ stock.
Furthermore, there will be NO DILUTION until 12/19 (and only 33% of shares issued in total for debt swap) 33% the following month and so on.
BRTXQ Stock Bottom Line
BRTXQ stock is a hidden gem on the OTC Markets. We know many investors refuse to buy because of the Q symbol. This is a huge missed opportunity on their part. Those investors think that once a company goes into bankruptcy that it’s all over. However, that’s not the case and why it is so important to read the case docs. Those that have are going to be laughing all the way to the bank as BRTXQ stock goes to a nickel, then a dime, then a quarter, and finally dollars. This incredible opportunity is at hand. Just need to do a little reading.
As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK TIP, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in OTCMKTS:BRTXQ, or any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.